DISCLOSED PROJECTS IMPLEMENTED
Due to a non-disclosure agreement with most our Clients, just the following information is publicly available:
- Most our Clients are international pharma/biotech companies (UCB Pharma, Janssen Cilag, GSK, Ranbaxy, Servier, LABKON, NEO ELEMENTUM, among others) and venture funds
- For over 800 compounds, drug candidates, products and formulations the global scientific and patent information has been targetly tracked and analyzed in most therapeutic areas (TAs)
- 250+ ad-hoc market research projects have been performed in most TAs
- 67 eligible small drug molecules/products have been provided with overall R&D expertise and lifecycle strategy modeling to be suggested for the development internationally: leriglitazone (Phase 2), lenalidomide (new indication, Phase 2-3), donepezil (new formulation, new indication, Phase 2), rotigotine (new indication, Phase 2), tacrolimus (new formulation, new dosage form, Phase unknown), pantoprazole (new dosage form, Phase 1), bexarotene (new indication, Phase unknown), isoniazid (new indication, Preclinical phase), maxacalcitol (new indication, new dosage form, Phase 3), levocarnitine (new salts, new indications, Phase 1-2), cyanocobalamin (new indication, Phase 2-3), among many others.
- 30 end-of-life generics have been analyzed and suggested as drug combination concepts for a new/expanded indication
and go-to-market strategy in Russia/CIS: olanzapine, fluoxetine, pantoprazole, domperidone, phenylephrine, tropicamide, levocarnitine, among many others. - Clinical pharmacological and medical scientific expertise on a philanthropic basis was provided for the product or TA strategic development for healthcare agencies and pharma companies in Russia, e.g. Ministry of Health (ARVs, HIV/AIDS), CHIESI Pharmaceuticals (Asthma & COPD Management), BIOCAD (Interferon-Beta Adverse Effects), Inbio Venture (HDAC Inhibitors, Cancer), Laboratoire INNOTECH INTERNATIONAL (Carbocysteine, Acetylcysteine), R-Pharm (Serinoprost, Glaucoma & IOP), etc.
SOME WORK SAMPLES
Product Lifecycle Strategy Analysis
Pan-HDAC Inhibitors Outlook for Cancer Treatment: A Brief Analysis (RUS)
Multiple Myeloma: Analysis of patient needs and treatment practices in Russia
Depression and Antidepressants: Statement of needs and physician prescribing patterns in Russia